A Phase 3 interventional study of FS MDPI and Fp MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 140 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-12.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 13th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 35 in phase 3, and was the 105th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 787 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 10th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2014, is one of 30 in phase 3, and was the 31st registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when administered over 12 weeks in patients 12 years of age and older with persistent asthma.
Study drug and placebo was supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.
Exclusion Criteria:
The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FS MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate
Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FS MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate
Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: Fp MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate
Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: Fp MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate
The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: Placebo MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate
FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist
Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Also known as: fluticasone propionate, inhaled corticosteroid
Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
Also known as: inert powder
Drug page: Albuterol
A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Also known as: short-acting β2-adrenergic agonists
QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
Also known as: QVAR
Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12
A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Data from these assessments were used to analyze the primary endpoint of baseline adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.
Time frame: Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Trough FEV1 was a morning spirometry taken predose and pre-rescue bronchodilator. If the patient inadvertently administered asthma medication/study drug at home on the AM of the visit, or if the patient took rescue medication within 6 hours of testing, the visit was rescheduled. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).
Time frame: Day 1 (predose, baseline), Week 12
Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.
Time frame: Days -6 to Day 1 (predose), Day 1 (postdose) daily until Week 12
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary (range 0-9). Daytime Symptom Score: 0=No symptoms 1. Symptoms for 1 short period 2. Symptoms for 2+ short periods 3. Symptoms for most of the day - did not affect normal daily activities 4. Symptoms for most of the day - did affect normal daily activities 5. Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): 0=No symptoms 1. Symptoms causing me to wake once (or wake early) 2. Symptoms causing me to wake twice or more (including waking early) 3. Symptoms causing me to be awake for most of the night 4. Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).
Time frame: Days -6 to Day 1 (predose, baseline) to Week 12
Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.
Time frame: Days -6 to Day 1 (predose, baseline), up to week 12
Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.
Time frame: up to Week 12 of the Treatment Period
Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self-administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score of 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.
Time frame: Day 1 (predose, baseline), end of trial (up to week 12)
Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Baseline FEV1 was the average of 2 FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, baseline was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of 9999 indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.
Time frame: Day 1 of the Treatment Period (predose and postdose)
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: Day 1 to Week 12 of the Treatment Period
A total of 1363 patients with persistent asthma were screened for enrollment into this study. 787 patients at 129 investigational centers in the US and elsewhere internationally met entry criteria and were considered eligible for enrollment into the study.
| Milestone | Enrolled Patients | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|---|
| Started | 787 | 0 | 0 | 0 | 0 | 0 |
| Completed | 647 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 140 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization criteria not met | 70 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 30 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Exclusion criteria met | 11 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 6 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Enrolled Patients | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|---|
| Started | 0 | 129 | 129 | 130 | 129 | 130 |
| Completed | 0 | 126 | 121 | 121 | 121 | 113 |
| Not completed | 0 | 3 | 8 | 9 | 8 | 17 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 | 1 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 2 | 3 | 2 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 1 | 4 |
| Withdrew: Other | 0 | 3 | 1 | 1 | 0 | 1 |
A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Data from these assessments were used to analyze the primary endpoint of baseline adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.
| liters | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12 | 0.408 ± 0.0465 | 0.399 ± 0.0479 | 0.254 ± 0.0434 | 0.268 ± 0.0457 | 0.074 ± 0.0487 |
Trough FEV1 was a morning spirometry taken predose and pre-rescue bronchodilator. If the patient inadvertently administered asthma medication/study drug at home on the AM of the visit, or if the patient took rescue medication within 6 hours of testing, the visit was rescheduled. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).
| liters | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 | 0.315 ± 0.0352 | 0.319 ± 0.0350 | 0.204 ± 0.0340 | 0.172 ± 0.0347 | 0.053 ± 0.0350 |
Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.
| liters/minute | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment | 24.415 ± 3.1530 | 24.864 ± 3.1182 | 14.517 ± 3.0778 | 10.609 ± 3.1176 | 3.591 ± 3.1474 |
The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary (range 0-9). Daytime Symptom Score: 0=No symptoms 1. Symptoms for 1 short period 2. Symptoms for 2+ short periods 3. Symptoms for most of the day - did not affect normal daily activities 4. Symptoms for most of the day - did affect normal daily activities 5. Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): 0=No symptoms 1. Symptoms causing me to wake once (or wake early) 2. Symptoms causing me to wake twice or more (including waking early) 3. Symptoms causing me to be awake for most of the night 4. Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).
| units on a scale | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period | -0.364 ± 0.0318 | -0.329 ± 0.0314 | -0.300 ± 0.0308 | -0.278 ± 0.0314 | -0.135 ± 0.0318 |
Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.
| puffs | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period | -0.677 ± 0.0937 | -0.706 ± 0.0930 | -0.466 ± 0.0915 | -0.467 ± 0.0928 | -0.003 ± 0.0937 |
The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.
| probability | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12 | 1.0000 (1.000 to 1.000) | 0.9917 (0.942 to 0.999) | 0.9919 (0.944 to 0.999) | 0.9919 (0.944 to 0.999) | 0.9681 (0.917 to 0.988) |
The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self-administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score of 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.
| units on a scale | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old | 0.808 ± 0.0728 | 0.565 ± 0.0752 | 0.636 ± 0.0736 | 0.588 ± 0.0733 | 0.335 ± 0.0777 |
A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Baseline FEV1 was the average of 2 FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, baseline was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of 9999 indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.
| hours | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| 15% improvement | 4.3 (1.070 to NA) | 1.3 (0.600 to 2.750) | NA (10.190 to NA) | NA (NA to NA) | NA (NA to NA) |
| 12% improvement | 1.0 (0.460 to 3.720) | 0.5 (0.300 to 1.550) | NA (7.370 to NA) | NA (3.890 to NA) | NA (7.270 to NA) |
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
| Participants | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| >=1 TEAE | 37 | 46 | 40 | 44 | 47 |
| >=1 severe TEAE | 2 | 0 | 1 | 1 | 0 |
| >=1 treatment-related TEAE | 4 | 4 | 5 | 7 | 5 |
| >=1 severe treatment-related TEAE | 0 | 0 | 0 | 0 | 0 |
| >=1 serious TEAE | 1 | 0 | 1 | 0 | 2 |
| >=1 TEAE leading to withdrawal | 0 | 3 | 2 | 1 | 6 |
| >=1 nonserious TEAE | 36 | 46 | 39 | 44 | 45 |
| >=1 TEAE resulting in death | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FS MDPI 100 / 12.5 mcg | — | 1/126 (0.8%) | 12/126 (9.5%) |
| FS MDPI 50 / 12.5 mcg | — | 0/128 (0%) | 22/128 (17.2%) |
| Fp MDPI 100 mcg | — | 1/129 (0.8%) | 21/129 (16.3%) |
| Fp MDPI 50 mcg | — | 0/129 (0%) | 15/129 (11.6%) |
| Placebo MDPI | — | 2/129 (1.6%) | 15/129 (11.6%) |
| Event | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| PancreatitisGastrointestinal disorders | 1/126 | 0/128 | 0/129 | 0/129 | 0/129 |
| CholecystitisHepatobiliary disorders | 1/126 | 0/128 | 0/129 | 0/129 | 0/129 |
| CholelithiasisHepatobiliary disorders | 1/126 | 0/128 | 0/129 | 0/129 | 0/129 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 0/128 | 1/129 | 0/129 | 0/129 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/126 | 0/128 | 0/129 | 0/129 | 1/129 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/126 | 0/128 | 0/129 | 0/129 | 1/129 |
| Event | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/126 | 11/128 | 9/129 | 7/129 | 4/129 |
| HeadacheNervous system disorders | 7/126 | 7/128 | 9/129 | 2/129 | 5/129 |
| Upper respiratory tract infectionInfections and infestations | 2/126 | 6/128 | 4/129 | 7/129 | 6/129 |
Intent to treat population
| Age, Continuous(years) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Mean | 41.0 ± 17.00 | 41.4 ± 18.61 | 40.6 ± 17.16 | 43.3 ± 17.96 | 40.9 ± 17.35 | 41.5 ± 17.60 |
| Age, Customized(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Adolescents (12-17 years) | 19 | 19 | 18 | 13 | 17 | 86 |
| Adults (18-64 years) | 100 | 97 | 102 | 93 | 102 | 494 |
| Adults (65+ years) | 10 | 13 | 10 | 23 | 11 | 67 |
| Sex: Female, Male(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Female | 72 | 71 | 76 | 75 | 70 | 364 |
| Male | 57 | 58 | 54 | 54 | 60 | 283 |
| Race/Ethnicity, Customized(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| White | 105 | 109 | 93 | 107 | 101 | 515 |
| Black or African American | 20 | 19 | 30 | 18 | 26 | 113 |
| Asian | 4 | 1 | 4 | 1 | 1 | 11 |
| American Indian or Alaskan Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 2 | 2 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 119 | 121 | 114 | 121 | 122 | 597 |
| Hispanic or Latino | 10 | 8 | 16 | 8 | 7 | 49 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 1 |
| Body Mass Index(kg/m^2) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Mean | 27.94 ± 6.686 | 28.00 ± 7.166 | 27.63 ± 6.603 | 27.94 ± 7.259 | 27.99 ± 6.849 | 27.90 ± 6.897 |
| History of Smoking(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Prior smoker | 18 | 13 | 15 | 14 | 12 | 72 |
| No tobacco use | 111 | 116 | 115 | 115 | 118 | 575 |
| Previous Asthma Therapy(Participants) | FS MDPI 100 / 12.5 mcg | FS MDPI 50 / 12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 50 mcg | Placebo MDPI | Total |
|---|---|---|---|---|---|---|
| Inhaled corticosteroid | 97 | 90 | 83 | 89 | 102 | 461 |
| Inhaled corticosteroid/long-acting beta2-agonist | 32 | 39 | 47 | 40 | 28 | 186 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 140 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Teva Branded Pharmaceutical Products R&D, Inc. →